All In Biotech

Drug Trial Radar · NCT03337308

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy

Last checked: Nov 19, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

382

Actual

Start

Oct 23, 2017

Primary completion

Jun 18, 2018

Study completion Jul 18, 2018

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy.

Conditions

  • Hyperlipidemias

Interventions

  • Bempedoic Acid + Ezetimibe Fixed-Dose CombinationCombination product

    bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet

  • Bempedoic AcidDrug

    bempedoic acid 180 mg tablet

  • EzetimibeDrug

    ezetimibe 10 mg overencapsulated tablet

  • PlacebosDrug

    placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline; Week 12

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • PMG Research of McFarland

    Ames, Iowa

  • Foundation Cardiology

    Nashua, New Hampshire

  • PMG Research of Piedmont Healthcare

    Statesville, North Carolina

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • PMG Research of Knoxville

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.